BioAge Labs (BIOA) EBITDA (2023 - 2026)

BioAge Labs has disclosed EBITDA across 4 years of filings, most recently posting -$22.5 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$22.5 million, down 73.97% year-over-year; the trailing twelve-month figure through Mar 2026 was -$90.1 million (down 27.0% YoY), and the FY2025 annual result was -$80.6 million, down 13.44% from the prior year.
• EBITDA came in at -$22.5 million for Q1 2026 at BioAge Labs, up from -$25.9 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$12.9 million in Q1 2025 to a low of -$25.9 million in Q4 2025.
• The 4-year median for EBITDA is -$21.0 million (2023), against an average of -$19.1 million.
• Across the five-year window, EBITDA increased 13.88% in 2025 and tumbled 73.97% in 2026, its largest moves.
• BioAge Labs' EBITDA stood at -$21.0 million in 2023, then decreased by 0.36% to -$21.1 million in 2024, then decreased by 22.92% to -$25.9 million in 2025, then advanced by 13.42% to -$22.5 million in 2026.
• The last three EBITDA figures came in at -$22.5 million (Q1 2026), -$25.9 million (Q4 2025), and -$20.1 million (Q3 2025), per Business Quant data.